Japan's Ministry Of Health, Labour And Welfare Has Accepted For Review GSK's New Drug Application For Blenrep (Belantamab Mafodotin) In Combination With Bortezomib Plus Dexamethasone Or Pomalidomide Plus Dexamethasone For Relapsed Or Refractory...
Japan's Ministry Of Health, Labour And Welfare Has Accepted For Review GSK's New Drug Application For Blenrep (Belantamab Mafodotin) In Combination With Bortezomib Plus Dexamethasone Or Pomalidomide Plus Dexamethasone For Relapsed Or Refractory...
日本衛生勞動省已經接受葛蘭素史克公司（GSK）的新藥申請，將Blenrep（貝倫替姆曲負散）與博蒂佐米布加替尼和地塞米松或泊馬度胺和地塞米松聯合使用治療複發性或難治性...
Japan's Ministry Of Health, Labour And Welfare Has Accepted For Review GSK's New Drug Application For Blenrep (Belantamab Mafodotin) In Combination With Bortezomib Plus Dexamethasone Or Pomalidomide Plus Dexamethasone For Relapsed Or Refractory Multiple Myeloma
日本的厚生勞動省已接受GSK的Blenrep（Belantamab Mafodotin）與硼替佐米加地塞米松或泊美度加地塞米松聯合用於復發或難治性多發性骨髓瘤的新藥申請進行審核
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。